Nash

(redirected from Nonalcoholic Steatohepatitis)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.

Nash

1. John. 1752--1835, English town planner and architect. He designed Regent's Park, Regent Street, and the Marble Arch in London
2. Ogden. 1902--71, US humorous poet
3. Paul. 1889--1946, English painter, noted esp as a war artist in both World Wars and for his landscapes
4. Richard, known as Beau Nash. 1674--1762, English dandy
5. Sir Walter. 1882--1968, New Zealand Labour statesman, born in England: prime minister of New Zealand (1957--60)
References in periodicals archive ?
Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with nonalcoholic steatohepatitis.
No associations were detected between the presence of nonalcoholic steatohepatitis or liver fibrosis and preoperative weight loss, weight gain, or body mass index.
Studies suggest that people who are overweight or obese have a substantially higher risk of nonalcoholic steatohepatitis (NASH).
The more serious types 3 (fat accumulation and ballooning degeneration) and 4 (fat accumulation, ballooning degeneration, and either Mallory hyaline and/or fibrosis) are characterized as nonalcoholic steatohepatitis (NASH).
DUR-928 is an endogenous, small-molecule, new chemical entity (NCE) that may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
ATLANTA -- A blood test can predict nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease, according to results of a study presented at a meeting sponsored by the American Association for the Study of Liver Diseases.
Benoit's presentation will include an overview of the company's development plans for its lead compound, MSDC-0602, which is expected to enter into large Phase 2b clinical trials in 2015 in patients diagnosed with nonalcoholic steatohepatitis known as NASH and polycystic kidney disease (PKD), respectively.
Among the remaining 48% with abnormal biopsy results, about 27% were found to have nonalcoholic fatty liver, and the others had nonalcoholic steatohepatitis.
A meta-analysis of trials examining the effects of vitamin E supplementation in individuals with nonalcoholic steatohepatitis (NASH) affirmed a benefit for the vitamin in association with several facets of the disease.
Raptor Pharma has declared topline results from the Phase 2b CyNCh study, which did not adhere to its primary endpoint of improving nonalcoholic steatohepatitis (NASH) in children.
Three quarters of HIV-positive adults with high liver enzymes and without viral hepatitis had undetected liver disease, (1) including more than half with nonalcoholic steatohepatitis (NASH *) (2) and fibrosis *, which can lead to permanent liver disease.